Problems of Plasma-Exchange Solutions, Gamma-Globulin Substitution, and Tumor Enhancement in Plasmapheresis of Tumor Patients

1982 ◽  
pp. 204-217
Author(s):  
J.-H. Beyer ◽  
M. Klee ◽  
U. Kaboth ◽  
A. Kehl ◽  
H. Köstering ◽  
...  
Keyword(s):  
Plasma Exchange ◽  
Gamma Globulin ◽  
Tumor Patients

Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin

2004 ◽  
Vol 14 (1) ◽  
pp. 43-47 ◽  
Author(s):  
Masaaki Mori ◽  
Tomoyuki Imagawa ◽  
Shigeki Katakura ◽  
Takako Miyamae ◽  
Ken-ichi Okuyama ◽  
...  
Keyword(s):  
Kawasaki Disease ◽  
Plasma Exchange ◽  
Gamma Globulin ◽  
Plasma Exchange Therapy ◽  
Intravenous Gamma Globulin

High-Dose Intravenous Gamma Globulin For Myasthenia Gravis: An Alternative to Plasma Exchange?

1987 ◽  
Vol 505 (1 Myasthenia Gr) ◽  
pp. 842-844 ◽  
Author(s):  
Ph. GAJDOS ◽  
H. D. OUTIN ◽  
E. MOREL ◽  
J. C. RAPHAEL ◽  
M. GOULON
Keyword(s):  
Myasthenia Gravis ◽  
Plasma Exchange ◽  
Gamma Globulin ◽  
High Dose ◽  
Intravenous Gamma Globulin

Abstract 129: Adaptation of Infliximab Therapy for Gamma Globulin Treatment Resistance Kawasaki Disease

Circulation ◽  
2015 ◽  
Vol 131 (suppl_2) ◽  
Author(s):  
Minako Hoshiai ◽  
Nobuyuki Katsumata ◽  
Yohei Hasebe ◽  
Keiichi Koizumi ◽  
Takako Toda ◽  
...  
Keyword(s):  
Kawasaki Disease ◽  
Plasma Exchange ◽  
Gamma Globulin ◽  
Clinical Symptoms ◽  
Laboratory Data ◽  
Treatment Resistance ◽  
Additional Treatment ◽  
Significant Other ◽  
The Disabled ◽  
Effective Group

Background: Infliximab (IFX) which is an anti-TNFα monoclonal antibody is effective in the treatment of gamma globulin treatment (IVIG) resistance Kawasaki disease (KD) . On the other hand, plasma exchange therapy (PE) became insurance adaptation as treatment for IVIG-resistant KD in Japan. It is necessary to clarify the position of IFX as an additional treatment for IVIG-resistant KD. Purpose: We examined retrospectively the efficacy of IFX for IVIG-resistant KD and discussed its adaptation. Method: We studied 30 cases (boys 18 cases, 12 cases of girls) who underwent IFX treatment in our hospital because they were IVIG-resistant KD. Between the invalid group and the effective group of IFX treatment, we compared the age , gender, the time of administration, the sick days, CRP value and the presence or absence of coronary artery lesions (CAL) before the treatment in patients. Result: Clinical symptoms and laboratory data has improved in 22 cases of the 30 cases, but 8 cases underwent plasma exchange because IFX was invalid. Compared to the disabled group and effective group of IFX, the proportion with CAL was significantly higher in the disabled group (87.5% invalid group 40.9% vs effective group, p <0.05). There was no significant other factor between the two group. Discussion: We have to suppressed the inflammation in order to inhibit CAL. To do so, the enforcement period and selection of additional treatment are important. Because treatable facility is limited, PE is not able to carry out in all cases. In this study, the possibility that can predict efficacy of IFX by the presence or absence of CAL in the IVIG-resistant KD has been shown. we should clarify the adaptation of IFX by continuing further study to find the relevant factors.

Electron Microscopy of Mycoplasma Pneumoniae

1971 ◽  
Vol 29 ◽  
pp. 258-259 ◽  
Author(s):  
E. S. Boatman ◽  
G. E. Kenny
Keyword(s):  
Electron Microscopy ◽  
Light Microscopy ◽  
Growth Phase ◽  
Hela Cells ◽  
Sulfonic Acid ◽  
Gamma Globulin ◽  
Horse Serum ◽  
Morphological Aspects ◽  
The Family

Information concerning the morphology and replication of organism of the family Mycoplasmataceae remains, despite over 70 years of study, highly controversial. Due to their small size observations by light microscopy have not been rewarding. Furthermore, not only are these organisms extremely pleomorphic but their morphology also changes according to growth phase. This study deals with the morphological aspects of M. pneumoniae strain 3546 in relation to growth, interaction with HeLa cells and possible mechanisms of replication.The organisms were grown aerobically at 37°C in a soy peptone yeast dialysate medium supplemented with 12% gamma-globulin free horse serum. The medium was buffered at pH 7.3 with TES [N-tris (hyroxymethyl) methyl-2-aminoethane sulfonic acid] at 10mM concentration. The inoculum, an actively growing culture, was filtered through a 0.5 μm polycarbonate “nuclepore” filter to prevent transfer of all but the smallest aggregates. Growth was assessed at specific periods by colony counts and 800 ml samples of organisms were fixed in situ with 2.5% glutaraldehyde for 3 hrs. at 4°C. Washed cells for sectioning were post-fixed in 0.8% OSO4 in veronal-acetate buffer pH 6.1 for 1 hr. at 21°C. HeLa cells were infected with a filtered inoculum of M. pneumoniae and incubated for 9 days in Leighton tubes with coverslips. The cells were then removed and processed for electron microscopy.

Ferritin-Conjugated Antibody for the Demonstration of Isoantigens on the Surface of Murine Cells

1968 ◽  
Vol 26 ◽  
pp. 48-49
Author(s):  
T. Aoki ◽  
J. Izard ◽  
U. Hämmerling ◽  
E. de Harven ◽  
L. J. Old
Keyword(s):  
Cell Surface ◽  
Gamma Globulin ◽  
Leukemia Cells ◽  
Labelling Technique ◽  
Direct Labelling ◽  
Labelling Method

Although a variety of viral and cellular antigens have been demonstrated by ferritin-labeled antibody, this technique has not been used to locate isoantigens on the surface of nucleated cells. The recognition of several systems of isoantigens on the surface of thymocytes, lymphocytes and leukemia cells of the mouse and the ease with which these cells can be obtained in free suspension led us to consider the ferritin-labelling method to determine the amount and location of these isoantigens on the cell surface. Because of the problems involved in the direct labelling of mouse gamma globulin by ferritin, we have chosen an indirect labelling technique (i.e. ferritin-conjugated rabbit anti mouse γG)to detect localization of mouse isoantibody.

Sign in / Sign up

Export Citation Format

Share Document